

## Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Therapeutic Targets During the COVID-19 Pandemic

Resource	Address
Manson JJ, et al. <b>COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study.</b> <i>Lancet Rheumatol.</i> 2020;2:e594-e602.	<a href="https://pubmed.ncbi.nlm.nih.gov/32864628/">https://pubmed.ncbi.nlm.nih.gov/32864628/</a>
Mikuls TR, et al. <b>American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.</b> <i>Arthritis Rheumatol.</i> 2020;72:1241-1251.	<a href="https://pubmed.ncbi.nlm.nih.gov/32349183/">https://pubmed.ncbi.nlm.nih.gov/32349183/</a>
Pablos JL, et al. <b>Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.</b> <i>Ann Rheum Dis.</i> 2020;79:1544-1549.	<a href="https://pubmed.ncbi.nlm.nih.gov/32796045/">https://pubmed.ncbi.nlm.nih.gov/32796045/</a>
Gianfrancesco M, et al. <b>Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.</b> <i>Ann Rheum Dis.</i> 2020;79:859-866.	<a href="https://pubmed.ncbi.nlm.nih.gov/32471903/">https://pubmed.ncbi.nlm.nih.gov/32471903/</a>
Brenner EJ, et al. <b>Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.</b> <i>Gastroenterology.</i> 2020;159:481-491.	<a href="https://pubmed.ncbi.nlm.nih.gov/32425234/">https://pubmed.ncbi.nlm.nih.gov/32425234/</a>
George M, et al. <b>Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic.</b> <i>J Rheumatol.</i> 2020;Epub ahead of print.	<a href="https://pubmed.ncbi.nlm.nih.gov/33191284/">https://pubmed.ncbi.nlm.nih.gov/33191284/</a>
Landewe RBM, et al. <b>EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.</b> <i>Ann Rheum Dis.</i> 2020;79:851-858.	<a href="https://pubmed.ncbi.nlm.nih.gov/32503854/">https://pubmed.ncbi.nlm.nih.gov/32503854/</a>
Singh JA, et al. <b>Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.</b> <i>Arthritis Rheumatol.</i> 2019;71:5-32.	<a href="https://pubmed.ncbi.nlm.nih.gov/30499246/">https://pubmed.ncbi.nlm.nih.gov/30499246/</a>
Mease PJ, et al. <b>Biologic Therapy for Psoriatic Arthritis.</b> <i>Rheum Dis N Am.</i> 2015;4:723-738.	<a href="https://pubmed.ncbi.nlm.nih.gov/26476229/">https://pubmed.ncbi.nlm.nih.gov/26476229/</a>

Mease PJ, et al. <b>Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.</b> <i>N Engl J Med.</i> 2015;373:1329-1339.	<a href="https://pubmed.ncbi.nlm.nih.gov/26422723/">https://pubmed.ncbi.nlm.nih.gov/26422723/</a>
McInnes IB, et al. <b>Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.</b> <i>Lancet.</i> 2015;386:1137-1146.	<a href="https://pubmed.ncbi.nlm.nih.gov/26135703/">https://pubmed.ncbi.nlm.nih.gov/26135703/</a>
Strand V, et al. <b>Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.</b> <i>Rheumatol Ther.</i> 2017;4:349-362.	<a href="https://pubmed.ncbi.nlm.nih.gov/28762213/">https://pubmed.ncbi.nlm.nih.gov/28762213/</a>
Thaci D, et al. <b>Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.</b> <i>JAAD.</i> 2015;73(3):400-409.	<a href="https://pubmed.ncbi.nlm.nih.gov/26092291/">https://pubmed.ncbi.nlm.nih.gov/26092291/</a>
Nash P, et al. <b>Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.</b> <i>Lancet.</i> 2017;389:2317-2327.	<a href="https://pubmed.ncbi.nlm.nih.gov/28551073/">https://pubmed.ncbi.nlm.nih.gov/28551073/</a>
Mease P, et al. <b>Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.</b> <i>Ann Rheum Dis.</i> 2017;76:79-87.	<a href="https://pubmed.ncbi.nlm.nih.gov/27553214/">https://pubmed.ncbi.nlm.nih.gov/27553214/</a>
Mease PJ, et al. <b>A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.</b> <i>Ann Rheum Dis.</i> 2020;79:123-131.	<a href="https://pubmed.ncbi.nlm.nih.gov/31563894/">https://pubmed.ncbi.nlm.nih.gov/31563894/</a>
Rolston VS, et al. <b>Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.</b> <i>Dig Dis Sci.</i> 2020;Epub ahead of print.	<a href="https://pubmed.ncbi.nlm.nih.gov/32445049/">https://pubmed.ncbi.nlm.nih.gov/32445049/</a>
McInnes I, et al. <b>Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.</b> <i>Lancet.</i> 2013;382:780-789.	<a href="https://pubmed.ncbi.nlm.nih.gov/23769296/">https://pubmed.ncbi.nlm.nih.gov/23769296/</a>

<b>Deodhar A, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF<math>\alpha</math> inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i>. 2020;395:1115-1125.</b>	<a href="https://pubmed.ncbi.nlm.nih.gov/32178765/">https://pubmed.ncbi.nlm.nih.gov/32178765/</a>
<b>Mease PJ, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i>. 2020;395:1126-1136.</b>	<a href="https://pubmed.ncbi.nlm.nih.gov/32178766/">https://pubmed.ncbi.nlm.nih.gov/32178766/</a>
<b>Gladman D, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>N Eng J Med</i>. 2017;377:1525-1536.</b>	<a href="https://pubmed.ncbi.nlm.nih.gov/29045207/">https://pubmed.ncbi.nlm.nih.gov/29045207/</a>
<b>Edwards CJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). <i>Ann Rheum Dis</i>. 2016;75:1065-1073.</b>	<a href="https://pubmed.ncbi.nlm.nih.gov/26792812/">https://pubmed.ncbi.nlm.nih.gov/26792812/</a>
<b>Mease PJ, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Ann Rheum Dis</i>. 2017;76:1550-1558.</b>	<a href="https://pubmed.ncbi.nlm.nih.gov/28473423/">https://pubmed.ncbi.nlm.nih.gov/28473423/</a>